Search by Drug Name or NDC
NDC 63090-0100-30 NUPLAZID 10 mg/1 Details
NUPLAZID 10 mg/1
NUPLAZID is a ORAL TABLET, COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Acadia Pharmaceuticals Inc.. The primary component is PIMAVANSERIN TARTRATE.
MedlinePlus Drug Summary
Pimavanserin is used to treat hallucinations and delusions in people with psychosis from Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance). Pimavanserin is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.
Related Packages: 63090-0100-30Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Pimavanserin
Product Information
NDC | 63090-0100 |
---|---|
Product ID | 63090-100_02c10e00-7f20-41ea-ad45-b239c8b7098a |
Associated GPIs | 59400028200310 |
GCN Sequence Number | 078604 |
GCN Sequence Number Description | pimavanserin tartrate TABLET 10 MG ORAL |
HIC3 | H8Y |
HIC3 Description | SELECTIVE SEROTONIN 5-HT2A INVERSE AGONISTS (SSIA) |
GCN | 44959 |
HICL Sequence Number | 043373 |
HICL Sequence Number Description | PIMAVANSERIN TARTRATE |
Brand/Generic | Brand |
Proprietary Name | NUPLAZID |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | pimavanserin tartrate |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET, COATED |
Route | ORAL |
Active Ingredient Strength | 10 |
Active Ingredient Units | mg/1 |
Substance Name | PIMAVANSERIN TARTRATE |
Labeler Name | Acadia Pharmaceuticals Inc. |
Pharmaceutical Class | Atypical Antipsychotic [EPC] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA207318 |
Listing Certified Through | 2024-12-31 |
Package
NDC 63090-0100-30 (63090010030)
NDC Package Code | 63090-100-30 |
---|---|
Billing NDC | 63090010030 |
Package | 30 TABLET, COATED in 1 BOTTLE, PLASTIC (63090-100-30) |
Marketing Start Date | 2018-06-28 |
NDC Exclude Flag | N |
Pricing Information | N/A |